Recombinant allergens for immunotherapy. Where do we stand?

Current Opinion in Allergy and Clinical Immunology

Volumn 4, Issue 6, 2004, Pages 549-554

  Niederberger, Verena ^a   Valenta, Rudolf ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Genetically modified; Hypoallergenic allergen derivatives; Immunotherapy; Recombinant allergen

Indexed keywords

ALLERGEN; ALLERGY VACCINE; PEPTIDE; RECOMBINANT ALLERGEN; UNCLASSIFIED DRUG; VACCINE;

ALLERGENICITY; B LYMPHOCYTE; CELL TYPE; DIAGNOSTIC TEST; DRUG EFFECT; DRUG FORMULATION; DRUG MECHANISM; GENETIC ENGINEERING; IMMUNOTHERAPY; MEDICAL TECHNOLOGY; MOLECULAR ANALYSIS; MOLECULAR BIOLOGY; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

ALLERGENS; ANIMALS; B-LYMPHOCYTES; DESENSITIZATION, IMMUNOLOGIC; HUMANS; HYPERSENSITIVITY, IMMEDIATE; T-LYMPHOCYTES; VACCINES, DNA;

EID: 9644259123     PISSN: 15284050     EISSN: None     Source Type: Journal    
DOI: 10.1097/00130832-200412000-00013     Document Type: Review

References (70)

1. Bousquet J, Lockey RF, Mailing HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998; 102:558-562.
2. Valenta R, Lidholm J, Niederberger V, et al The recombinant allergen-based concept of component-resolved diagnostics and immunotherapy (CRD and CRIT). Clin Exp Allergy 1999; 29:896-904.
3. Valenta R, Kraft D. From allergen structure to new forms of allergen-specific immunotherapy. Curr Opin Immunol 2002; 14:718-727.
4. Valenta R, Kraft D, editors. Recombinant allergens. Methods 2004; 32:207-345. This complete issue of Methods discussed topics from the basics to clinical applications of recombinant allergens.
5. Harwanegg C, Laffer S, Hiller R, et al. Microarrayed recombinant allergens for diagnosis of allergy. Clin Exp Allergy 2003; 33:7-13.
6. Van der Veen MJ, Mulder M, Witteman AM, et al. False-positive skin prick test responses to commercially available dog dander extracts caused by contamination with house dust mite. J Allergy Clin Immunol 1996; 98:1028-1034.
7. Akkerdaas JH, Wensing M, Knulst AC, et al. How accurate and safe is the diagnosis of hazelnut allergy by means of commercial skin prick test reagents? Int Arch Allergy Immunol 2003; 132:132-140.
8. Marth K, Focke M, Flicker S, Valenta R. Human monoclonal antibody-based quantification of group 2 grass pollen allergens. J Allergy Clin Immunol 2004; 113:470-474.
9. Trivedi B, Valerio C, Slater JE. Endotoxin content of standardized allergen vaccines. J Allergy Clin Immunol 2003; 111:777-783. The authors describe detection of unexpected high levels of endotoxins in commercial allergen extract preparations.
10. Braun-Fahrländer C, Riedler J, Herz U, et al. Environmental exposure to endotoxin and its relation to asthma in school-age children. N Engl J Med 2002; 347:869-877.
11. Eisenbarth SC, Piggott DA, Huleatt JW, et al. Lipopolysaccharide- enhanced, toll-like receptor 4-dependent T helper cell type 2 responses to inhaled antigen. J Exp Med 2002; 196:1645-1651.
12. Mothes N, Heinzkill M, Drachenberg KJ, et al. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvant vaccine: reduced seasonally boosted IgE production and inhibition of basophil histamine release by blocking antibodies. Clin Exp Allergy 2003; 33:1198-1208. Monitoring of immunotherapy with recombinant grass pollen allergens reveals the heterogeneity of induced immune responses and mechanisms underlying immunotherapy.
13. Ball T, Sperr WR, Valent P, et al. Induction of antibody responses to new B cell epitopes indicates vaccination character of allergen immunotherapy. Eur J Immunol 1999; 29:2026-2036.
14. Movérare R, Elfman L, Vesterinen E, et al. Development of new IgE specificities to allergenic components in birch pollen extract during specific immunotherapy studied with immunoblotting and Pharmacia CAP system. Allergy 2002; 57:423-430.
15. van Hage-Hamsten M, Valenta R. Specific immunotherapy: the induction of new IgE specificities? Allergy 2002; 57:375-378.
16. Valenta R. The future of antigen-specific immunotherapy of allergy. Nat Rev Immunol 2002; 2:446-453.
17. Valenta R, Ball T, Focke M, et al. Immunotherapy of allergic disease. Adv Immunol 2004; 82:105-153. This is a comprehensive overview of immunotherapy strategies for allergy.
18. Vrtala S, Akdis C, Budak F, et al. T cell epitope-containing hypoallergenic recombinant fragments of the major birch pollen allergen, Bet v 1, induce blocking antibodies. J Immunol 2000; 165:6653-6659.
19. Vrtala S, Hirtenlehner K, Susani M, et al. Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen, Bet v 1. FASEB J 2001; 15:2045-2047.
20. Korematsu S, Tanaka Y, Hosoi S, et al. C8/119S mutation of major mite allergen Der f-2 leads to degenerate secondary structure and molecular polymerization and induces potent and exclusive Th1 cell differentiation. J Immunol 2000; 165:2895-2902.
21. Linhart B, Hartl A, Jahn-Schmid B, et al. Combination vaccines for the treatment of grass pollen allergy consisting of genetically engineered hybrid molecules with increased immunogenicity. FASEB J 2002; 16:1301-1303.
22. Linhart B, Valenta R. Vaccine engineering improved by hybrid technology. Int Arch Allergy Immunol 2004; 134:324-331.
23. Kazemi-Shirazi L, Niederberger V, Linhart B, et al. Recombinant marker allergens: Diagnostic gatekeepers for the treatment of allergy. Int Arch Allergy Immunol 2002; 127:259-268.
24. Pauli G. Evolution in the understanding of cross-reactivities of respiratory allergens: the role of recombinant allergens. Int Arch Allergy Immunol 2000; 123:183-195.
25. Stumvoll S, Westritschnig K, Lidholm J, et al. Identification of cross-reactive and genuine Parietaria judaica pollen allergens. J Allergy Clin Immunol 2003; 111:974-979.
26. Pittner G, Vrtala S, Thomas WR, et al. Component-resolved diagnosis of house-dust mite allergy with purified natural and recombinant mite allergens. Clin Exp Allergy 2004; 34:597-603.
27. Swoboda I, Grate M, Verdino P, et al. Molecular characterization of polygalacturonases as grass pollen-specific marker allergens: expulsion from pollen via submicronic respirable particles. J Immunol 2004; 172:6490-6500.
28. Grönlund H, Bergman T, Sandstrom K, et al. Formation of disufide bonds and homodimers of the major cat allergen FeI d 1 equivalent to the natural allergen by expression in Escherichia coli. J Biol Chem 2003; 278:40144-40150.
29. Reininger R, Swoboda I, Bohle B, et al. Characterization of recombinant cat albumin. Clin Exp Allergy 2003; 33:1695-1702.
30. Mothes N, Horak F, Valenta R. The transition from a botanical to a molecular classification in tree pollen allergy: Implications for diagnosis and therapy. Int Arch Allergy Immunol (in press).
31. Swoboda I, Bugajska-Schretter A, Verdino P, et al. Recombinant carp parvalbumin, the major cross-reactive fish allergen: tool for diagnosis and therapy of fish allergy. J Immunol 2002; 168:4576-4584.
32. Rossi RE, Monasterolo G. Evaluation of recombinant and native timothy grass pollen (rPhI p 1, 2, 5, 6, 7, 11, 12 and nPhI p 4)-specific IgG4 antibodies induced by subcutaneous immunotherapy with timothy pollen extract in allergic patients. Int Arch Allergy Immunol 2004; 135:44-53.
33. Bolhaar ST, Tiemessen MM, Zuidmeer L, et al. Efficacy of birch-pollen immunotherapy on cross-reactive food allergy confirmed by skin tests and double-blind food challenges. Clin Exp Allergy 2004; 34:761-769.
34. Flicker S, Valenta R. Renaissance of the blocking antibody concept in type I allergy. Int Arch Allergy Immunol 2003; 132:13-24.
35. Wachholz PA, Soni NK, Till SJ, Durham SR. Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. J Allergy Clin Immunol 2003; 112:915-922.
36. Nouri-Aria KT, Wachholz PA, Francis JN, et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol 2004; 172:3252-3259.
37. Wachholz, PA, Durham SR. Induction of "blocking" IgG antibodies during Immunotherapy. Clin Exp Allergy 2003; 33:1171-1174.
38. Hardy CL, Rolland JM, O'Hehir RE. Blocking antibodies in allergen immunotherapy: the Yin and Yang. Clin Exp Allergy 2004; 34:510-512.
39. Van Neerven RJ, Arvidsson M, Ipsen H, et al. A double-blind, placebo-controlled birch allergy vaccination study: inhibition of CD23-mediated serum-immunoglobulin E-facilitated allergen presentation. Clin Exp Allergy 2004; 34:420-428.
40. De Weerd N, Bhalla PL, Singh MB. Oral immunization with a recombinant major grass pollen allergen induces blocking antibodies in mice. Int Arch Allergy Immunol 2003; 130:119-124.
41. Orlandi A, Grasso F, Corinti S, et al. The recombinant major allergen of Paritaria judaica and its hypoallergenic variant: in vivo evaluation in a murine model of allergic sensitization. Clin Exp Allergy 2004; 34:470-477.
42. Hufnagl K, Wagner B, Winkler B, et al. Induction of mucosal tolerance with recombinant Hev b 1 and recombinant Hev b 3 for prevention of latex allergy in BALB/c mice. Clin Exp Immunol 2003; 133:170-176.
43. Winkler B, Bolwig C, Seppala U, et al. Allergen-specific immunosuppression by mucosal treatment with recombinant Ves v 5, a major allergen of Vespula vulgaris venom, in a murine model of wasp venom allergy. Immunology 2003; 110:376-385.
44. Jutel M, Jäger L, Meyer H, et al. Specific immunotherapy with recombinant grass pollen allergens is clinically efficacious [abstract]. Proceedings of the XXIII European Congress of Allergology and Clinical Immunology; 12-16 June 2004; Amsterdam. Hannover: Pharmaservice; 2004. p. 137.
45. Fiebig H, Weber B, Suck R, et al. Specific antibody responses during immunotherapy with a recombinant grass pollen allergen cocktail [abstract]. Proceedings of the XXIII European Congress of Allergology and Clinical Immunology; 12-16 June 2004; Amsterdam. Hannover: Pharmaservice; 2004. p. 147.
46. Tighe H, Takabayashi K, Schwartz D, et al. Conjugation of immunostimulatory DNA to the short ragweed allergen Amb a 1 enhances its immunogenicity and reduces its allergenicity. J Allergy Clin Immunol 2000; 106:124-134.
47. H2 cytokine expression in PBMCs from human patients with ragweed allergy. J Allergy Clin Immunol 2001; 108:191-197.
48. Tulic MK, Fiset PO, Christodoulopoulos P, et al. Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. J Allergy Clin Immunol 2004; 113:235-241.
49. Creticos PS, Lighvani SS, Bieneman AP, et al. Enhanced IL-10 secretion by PBMC during the ragweed season: Effect of AIC immunotherapy vs placebo [abstract]. J Allergy Clin Immunol 2003; 111:8201.
50. Bohle B, Breitwieser A, Zwölfer B, et al. A novel approach to specific allergy treatment: the recombinant fusion protein of a bacterial cell surface (S-layer) protein and the major birch pollen allergen Bet v 1 (rSbsC-Bet v 1) combines reduced allergenicity with immunomodulating capacity. J Immunol 2004; 172:6642-6648.
51. Liu YH, Kao MC, Lai YL, Tsai JJ. Efficacy of local nasal immunotherapy for Dp2-induced airway inflammation in mice: Using Dp2 peptide and fungal immunomodulatory peptide. J Allergy Clin Immunol 2003; 112:301-310.
52. Li XM, Srivastava K, Huleatt JW, et al. Engineered recombinant peanut protein and heat-killed Listeria monocytogenes coadministration protects against peanut-induced anaphylaxis in a murine model. J Immunol 2003; 170:3289-3295.
53. Walter F, Scholl I, Untersmayr E, et al. Functionalisation of allergen-loaded microspheres with wheat germ agglutinin for targeting enterocytes. Biochem Biophys Res Comm 2004; 315:281-287.
54. Scholl I, Weissenböck A, Förster-Waldl E, et al. Allergen-loaded biodegradable poly (D,L-lactic-co-glycolic) acid nanoparticles downregulate an ongoing Th2 response in the BALB/c mouse model. Clin Exp Allergy 2004; 34:315-321.
55. Arikan C, Bahceciler NN, Deniz G, et al. Bacillus Calmette-Guerin-induced interleukin-12 did not additionally improve clinical and immunologic parameters in asthmatic children treated with sublingual immunotherapy. Clin Exp Allergy 2004; 34:398-405.
56. Fellrath JM, Kettner A, Dufour N, et al. Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: results of a phase I trial. J Allergy Clin Immunol 2003; 111:854-861.
57. Oldfield WLG, Larché M, Kay AB. Effect of T-cell peptides derived from FeI d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised control trial. Lancet 2002; 360:47-53.
58. Focke M, Mahler V, Ball T, et al. Nonanaphylactic peptides derived from B cell epitopes of the major grass pollen allergen, PhI p 1, for allergy vaccination. FASEB J 2001; 15:2042-2044.
59. Westritschnig K, Focke M, Verdino P, et al. Generation of an allergy vaccine by disruption of the three-dimensional structure of the cross-reactive calcium-binding allergen, PhI p 7. J Immunol 2004; 172:5684-5692.
60. Focke M, Linhart B, Hartl A, et al. Non-anaphylactic surface-exposed peptides of the major birch pollen allergen, Bet v 1, for preventive vaccination. Clin Exp Allergy (in press).
61. Ganglberger E, Grünberger K, Wiedermann U, et al. IgE mimotopes of birch pollen allergen Bet v 1 induce blocking IgG in mice. Int Arch Allergy Immunol 2001; 124:395-397.
62. Scholl I, Wiedermann U, Förster-Waldl E, et al. Phage-displayed Bet mim 1, a mimotope of the major birch pollen allergen Bet v 1, induces B cell responses to the natural antigen using bystander T cell help. Clin Exp Allergy 2002; 32:1583-1588.
63. van Hage-Hamsten M, Kronqvist M, Zetterstrom O, et al. Skin test evaluation of genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1: results obtained with a mix of two recombinant Bet v 1 fragments and recombinant Bet v 1 trimer in a Swedish population before the birch pollen season. J Allergy Clin Immunol 1999; 104:969-977.
64. Pauli G, Purohit A, Oster JP, et al. Comparison of genetically engineered hypoallergenic rBet v 1 derivatives with rBet v 1 wild-type by skin prick and intradermal testing: results obtained in a French population. Clin Exp Allergy 2000; 30:1076-1084.
65. Nopp A, Hallden G, Lundahl J, et al. Comparison of inflammatory responses to genetically engineered hypoallergenic derivatives of the major birch pollen allergen Bet v 1 and to recombinant Bet v 1 wild type in skin chamber fluids collected from birch pollen allergic patients. J Allergy Clin Immunol 2000; 106:101-109.
66. van-Hage Hamsten M, Johansson E, Roquet A, et al. Nasal challenges with recombinant derivatives of the major birch pollen allergen Bet v 1 induce fewer symptoms and lower mediator release than rBet v 1 wild-type in patients with allergic rhinitis. Clin Exp Allergy 2002; 32:1448-1453.
67. Arquint O, Helbling A, Crameri R, et al. Reduced in vivo allergenicity of Bet v 1 d isoform, a natural component of birch pollen. J Allergy Clin Immunol 1999; 104:1239-1243.
68. Mahler V, Vrtala S, Kuss O, et al. Vaccines for birch pollen allergy based on genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1. Clin Exp Allergy 2004; 34:115-122.
69. Niederberger V, Horak F, Vrtala S, et al. Development of a novel allergy vaccine: Genetically modified allergens prevent progression of allergic disease. Proc Natl Acad Sci U S A 2004 [Epub ahead of print]. The first clinical study in which patients were treated by immunotherapy with recombinant allergen derivatives.
70. Thunberg S, Gafvelin G, Grönlund H, et al. A novel allergy vaccine based on genetically modified allergens induce immunological alterations in birch pollen allergic patients [abstract]. Proceedings of the XXIII European Congress of Allergology and Clinical Immunology; 12-16 June 2004; Amsterdam. Hannover: Pharmaservice; 2004. p. 144.